Moberg Pharma Valuation

Q: What is the Fair Price of MB8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MB8 (€3.2) is trading above our estimate of [[fair value]] (€0.58)

Is MB8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MB8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MB8 (€3.2) is trading above our estimate of fair value (€0.58)

Significantly Below Fair Value: MB8 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MB8?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MB8. This is calculated by dividing MB8's market cap by their current preferred multiple.
What is MB8's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	kr1.02b

MB8 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-35.9x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MB8's PB Ratio compare to its peers?

The above table shows the PB ratio for MB8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.7x
93M1 MPH Health Care	0.4x	-22.0%	€92.5m
APPH Apontis Pharma	2.3x	79.9%	€68.8m
2FJ0 Pierrel	3.6x	n/a	€92.8m
0RX Redx Pharma	16.6x	-22.3%	€65.0m
MB8 Moberg Pharma	1.7x	47.6%	€1.0b

Price-To-Book vs Peers: MB8 is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (5.7x).

Price to Earnings Ratio vs Industry

How does MB8's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	20.7%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	20.7%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: MB8 is good value based on its Price-To-Book Ratio (1.7x) compared to the European Pharmaceuticals industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is MB8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MB8 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MB8's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.